z-logo
open-access-imgOpen Access
Perindopril is angiotensin-converting enzyme inhibitor in treatment patients with arterial hypertension
Author(s) -
А И Мартынов,
I V Urlaeva,
Ye.V. Akatova,
O P Nikolin
Publication year - 2014
Publication title -
systemic hypertension
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg29051
Subject(s) - perindopril , medicine , angiotensin converting enzyme , ace inhibitor , antagonist , pharmacology , incidence (geometry) , myocardial infarction , drug , cardiology , blood pressure , receptor , physics , optics
According to the 2013 ESH guidelines, it is possible to use any group of known antihypertensive drugs in the treatment of arterial hypertension. But we often have been using different combinations of drugs. In this situation, using drugs combination in fixed dosage increases patients acceptance of therapy and makes treatment easier. According to the results of the numerous studies, perindopril statistically significant reduces total and cardiovascular mortality and the incidence of myocardial infarction. The combination of perindopril and calcium antagonist makes the drug more effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom